Primary prevention of cardiovascular disease Circulatory System
Conditions
Interventions
Participants will be randomised 1:1 by the researcher using opaque sealed randomisation envelopes containing randomisation cards with a two-letter code to represent the allocation. The randomisation e
Sponsors
University of Birmingham
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged between 30 and 84 years inclusive. This is because the heart age tool can only be accessed by people aged 30 and above and NICE recommend CVD risk assessment up to the age of 84 2. QRISK2 score = 10%, as it is these patients who are referred to the doctor for further assessment as per NICE guidelines 3. Able to attend the GP practice for appointments 4. Able to give informed consent
Exclusion criteria
Exclusion criteria: 1. Prior history of CVD 2. Known high risk of CVD where NICE does not recommend CVD risk assessment: type 1 diabetes, chronic kidney disease stage 3 or higher and familial hypercholesterolaemia 3. Palliative care patients on the gold standards framework register 4. Unable to speak and understand written and verbal English 5. Pregnant women 6. Currently or recently (last 6 months) been involved in other research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The feasibility of using heart age for CVD risk communication, including: 1. Acceptability of heart age to patients and GPs: measured by an internally developed score (5-point Likert scale) towards the end of the study (June-July 2018) 2. Recruitment and retention of participants: to be measured throughout the study using a tally chart and the percentage of participants that were lost to follow-up 3. Completeness and range of data: to be measured throughout the study using percentages 4. Fidelity of the delivery of the heart age intervention: to be measured using a digital audio recorder at the GP consultation during the first part of the study (Feb-April 2018) 5. Feasibility of the trial procedures: no single measurement or time point but will be assessed throughout the study and at the end | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. CVD risk factors (blood tests and clinical measurements) measured at baseline and at the end of the study (June-July 2018) 2. Health behaviours (smoking, alcohol, diet, physical activity) measured at baseline and at the end of the study (June-July 2018) 3. QRISK2 and heart age scores measured at baseline and at the end of the study (June-July 2018) 4. Statin medication use assessed at baseline and at the end of the study (June-July 2018) 5. GP consulted, assessed towards the beginning of the study (Feb-April 2018) | — |
Countries
England, United Kingdom
Outcome results
None listed